JP2013534227A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534227A5
JP2013534227A5 JP2013524362A JP2013524362A JP2013534227A5 JP 2013534227 A5 JP2013534227 A5 JP 2013534227A5 JP 2013524362 A JP2013524362 A JP 2013524362A JP 2013524362 A JP2013524362 A JP 2013524362A JP 2013534227 A5 JP2013534227 A5 JP 2013534227A5
Authority
JP
Japan
Prior art keywords
nasal
nose
powder
ingested
sucking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013524362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534227A (ja
JP6049617B2 (ja
Filing date
Publication date
Priority claimed from DE102010034699A external-priority patent/DE102010034699A1/de
Application filed filed Critical
Publication of JP2013534227A publication Critical patent/JP2013534227A/ja
Publication of JP2013534227A5 publication Critical patent/JP2013534227A5/ja
Application granted granted Critical
Publication of JP6049617B2 publication Critical patent/JP6049617B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013524362A 2010-08-18 2011-07-19 Ｆａｋ阻害剤としてのピリミジン誘導体 Expired - Fee Related JP6049617B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010034699A DE102010034699A1 (de) 2010-08-18 2010-08-18 Pyrimidinderivate
DE102010034699.3 2010-08-18
PCT/EP2011/003597 WO2012022408A1 (de) 2010-08-18 2011-07-19 Pyrimidinderivate als fak inhibitoren

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016153334A Division JP6441861B2 (ja) 2010-08-18 2016-08-04 Ｆａｋ阻害剤としてのピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2013534227A JP2013534227A (ja) 2013-09-02
JP2013534227A5 true JP2013534227A5 (enExample) 2016-01-07
JP6049617B2 JP6049617B2 (ja) 2016-12-21

Family

ID=44504442

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013524362A Expired - Fee Related JP6049617B2 (ja) 2010-08-18 2011-07-19 Ｆａｋ阻害剤としてのピリミジン誘導体
JP2016153334A Expired - Fee Related JP6441861B2 (ja) 2010-08-18 2016-08-04 Ｆａｋ阻害剤としてのピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016153334A Expired - Fee Related JP6441861B2 (ja) 2010-08-18 2016-08-04 Ｆａｋ阻害剤としてのピリミジン誘導体

Country Status (17)

Country Link
US (1) US8906916B2 (enExample)
EP (1) EP2606034B1 (enExample)
JP (2) JP6049617B2 (enExample)
CN (1) CN103052627B (enExample)
AR (1) AR082722A1 (enExample)
AU (1) AU2011291110B2 (enExample)
CA (1) CA2808540C (enExample)
DE (1) DE102010034699A1 (enExample)
DK (1) DK2606034T3 (enExample)
ES (1) ES2572740T3 (enExample)
HR (1) HRP20160562T1 (enExample)
HU (1) HUE027846T2 (enExample)
IL (1) IL224751A (enExample)
PL (1) PL2606034T3 (enExample)
RS (1) RS54882B1 (enExample)
SI (1) SI2606034T1 (enExample)
WO (1) WO2012022408A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010034699A1 (de) * 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
JP5937111B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ Ｆａｋ阻害剤
EP2675794B1 (en) * 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
CN104736533B (zh) * 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
HK1209104A1 (en) 2012-08-17 2016-03-24 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
JPWO2014174745A1 (ja) * 2013-04-26 2017-02-23 国立大学法人京都大学 Ｅｇ５阻害剤
WO2015054477A1 (en) 2013-10-09 2015-04-16 The General Hospital Corporation Methods of diagnosing and treating b cell acute lymphoblastic leukemia
WO2015123722A1 (en) * 2014-02-19 2015-08-27 Bionomics Limited Inhibitors
WO2016033100A1 (en) * 2014-08-25 2016-03-03 Salk Institute For Biological Studies Novel ulk1 inhibitors and methods using same
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
EP2090571B1 (de) * 2001-10-17 2012-05-16 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
EP1495016A2 (en) * 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
OA13309A (en) 2002-12-20 2007-04-13 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2006110763A1 (en) * 2005-04-08 2006-10-19 Bayer Pharmaceuticals Corporation Pyrimidine derivatives and their use for the treatment of cancer
EP2727909A1 (en) 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
NZ624345A (en) * 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
TW201024281A (en) * 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
DE102010034699A1 (de) * 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
EP2675794B1 (en) * 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
JP5937111B2 (ja) * 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ Ｆａｋ阻害剤

Similar Documents

Publication Publication Date Title
JP2014509313A5 (enExample)
JP2013534227A5 (enExample)
JP2014526447A5 (enExample)
JP2013544781A5 (enExample)
JP2013541565A5 (enExample)
JP2015505541A5 (enExample)
Doktorovova et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation
JP2013538214A5 (enExample)
RU2015121091A (ru) Порошки для ингаляции с ультранизкой плотностью
EA201590286A1 (ru) Аэрозольное ингаляционное устройство
MX371521B (es) Sistema de inhalacion de polvo seco.
BR112013022249B8 (pt) Dispositivo de distribuição de droga nasal
CL2013000153A1 (es) Metodo para entregar una solucion de un medicamento a un ojo de un sujeto que lo necesita, comprende, el proveer gotitas que contienen dicho medicamento, en donde dichas gotitas tienen un tamaño promedio de gotita por lo menos de aproximadamente 15 micrones y una velocidad de eyeccion inicial promedio entre 1 m/s y 5 m/s, y entregar dicho medicamento a dicho ojo, donde entre aproximadamente 80% y 100% de la masa de dichas gotitas es depositado en el ojo.
WO2014012069A3 (en) Dry powder drug delivery systems and methods
JP2017502064A5 (enExample)
ATE527976T1 (de) Vorrichtung zur lagerung, unmittelbaren zubereitung und verabreichung eines wirkstoffes
EA201591729A1 (ru) Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства
WO2010029441A3 (en) Nasal delivery
WO2012051426A3 (en) Aggregate nanoparticulate medicament formulations, manufacture and use thereof
WO2013155201A3 (en) Spray ejector mechanisms and devices providing charge isolation and controllable droplet charge, and low dosage volume opthalmic administration
WO2013090841A3 (en) Aerosolization apparatus for inhalation profile-independent drug delivery
EA201591869A1 (ru) Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
WO2013038268A8 (en) Tamper resistant immediate release formulations